Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CALIFORNIA HEALTH CAPITATION PLANS HAVE "SLIM CHANCE"

Executive Summary

CALIFORNIA HEALTH CAPITATION PLANS HAVE "SLIM CHANCE" of passing the California state legislature this session, state Senator Diane Watson noted at a state govt. affairs breakfast at PMA's annual meeting. Asked if she envisioned a capitation program this year or next, Watson responded that there are four bills in the state legislature, one of which has passed the Senate and is in the Assembly's Health Cmte. "The chance of any capitation bill passing this session are slim, if none," she declared. Watson said the bills are "competing pieces of legislation" and the legislature has "not come to any agreement as to which will be the lead vehicle." Watson asserted that two issues need to be addressed in the pending capitation proposals: co-payment and access to health care. "We're dealing with a welfare-eligible group of participants and it is impractical to think that these people can come in with $25 to the emergency room," Watson stated. She maintained that co-payment for medical services should be eliminated. In addition, the capitation system should be designed to assure reasonable access, Watson said. "We want to be sure we can define what a region is so that we won't have voids in service as I have in my district, so people won't have to travel 45 miles to be admitted into a hospital." Under current California Medi-Cal reforms, the state is experiencing problems with access to care, she contended. Watson said providers are asked to package services and "give a set fee to the Medicaid authorities as their operational fees" for the prospective year. However, she observed, "we're getting feedback that there are all kinds of cost overruns" and "we're finding more doctors are opting out of the Medi-Cal business in the state of Caifornia." PMA's Woodrow Allen said the assn. "does not have a defined position pro or con on capitation." He said that PMA has a health care financing cmte. assessing the issue to determine what position the assn. should take.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS006552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel